220 related articles for article (PubMed ID: 26608920)
1. CD137 Agonist Therapy Can Reprogram Regulatory T Cells into Cytotoxic CD4+ T Cells with Antitumor Activity.
Akhmetzyanova I; Zelinskyy G; Littwitz-Salomon E; Malyshkina A; Dietze KK; Streeck H; Brandau S; Dittmer U
J Immunol; 2016 Jan; 196(1):484-92. PubMed ID: 26608920
[TBL] [Abstract][Full Text] [Related]
2. An Immunotherapeutic CD137 Agonist Releases Eomesodermin from ThPOK Repression in CD4 T Cells.
Mittal P; Abblett R; Ryan JM; Hagymasi AT; Agyekum-Yamoah A; Svedova J; Reiner SL; St Rose MC; Hanley MP; Vella AT; Adler AJ
J Immunol; 2018 Feb; 200(4):1513-1526. PubMed ID: 29305435
[TBL] [Abstract][Full Text] [Related]
3. Eomesodermin Expression in CD4+ T Cells Restricts Peripheral Foxp3 Induction.
Lupar E; Brack M; Garnier L; Laffont S; Rauch KS; Schachtrup K; Arnold SJ; Guéry JC; Izcue A
J Immunol; 2015 Nov; 195(10):4742-52. PubMed ID: 26453746
[TBL] [Abstract][Full Text] [Related]
4. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
[TBL] [Abstract][Full Text] [Related]
5. Agonist anti-CD137 mAb act on tumor endothelial cells to enhance recruitment of activated T lymphocytes.
Palazón A; Teijeira A; Martínez-Forero I; Hervás-Stubbs S; Roncal C; Peñuelas I; Dubrot J; Morales-Kastresana A; Pérez-Gracia JL; Ochoa MC; Ochoa-Callejero L; Martínez A; Luque A; Dinchuk J; Rouzaut A; Jure-Kunkel M; Melero I
Cancer Res; 2011 Feb; 71(3):801-11. PubMed ID: 21266358
[TBL] [Abstract][Full Text] [Related]
6. Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.
Taraban VY; Rowley TF; O'Brien L; Chan HT; Haswell LE; Green MH; Tutt AL; Glennie MJ; Al-Shamkhani A
Eur J Immunol; 2002 Dec; 32(12):3617-27. PubMed ID: 12516549
[TBL] [Abstract][Full Text] [Related]
7. Treatment-enhanced CD4+Foxp3+ glucocorticoid-induced TNF receptor family related high regulatory tumor-infiltrating T cells limit the effectiveness of cytokine-based immunotherapy.
Berhanu A; Huang J; Watkins SC; Okada H; Storkus WJ
J Immunol; 2007 Mar; 178(6):3400-8. PubMed ID: 17339434
[TBL] [Abstract][Full Text] [Related]
8. Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.
Sica G; Chen L
Arch Immunol Ther Exp (Warsz); 1999; 47(5):275-9. PubMed ID: 10604232
[TBL] [Abstract][Full Text] [Related]
9. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation.
Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S
Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763
[TBL] [Abstract][Full Text] [Related]
10. 4-1BB (CD137) ligand enhanced anti-tumor immune response against mouse forestomach carcinoma in vivo.
Li Q; Ai J; Song Z; Liu J; Shan B
Cell Mol Immunol; 2008 Oct; 5(5):379-84. PubMed ID: 18954562
[TBL] [Abstract][Full Text] [Related]
11. Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors.
Zhang N; Sadun RE; Arias RS; Flanagan ML; Sachsman SM; Nien YC; Khawli LA; Hu P; Epstein AL
Clin Cancer Res; 2007 May; 13(9):2758-67. PubMed ID: 17460060
[TBL] [Abstract][Full Text] [Related]
12. The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy.
Palazón A; Martínez-Forero I; Teijeira A; Morales-Kastresana A; Alfaro C; Sanmamed MF; Perez-Gracia JL; Peñuelas I; Hervás-Stubbs S; Rouzaut A; de Landázuri MO; Jure-Kunkel M; Aragonés J; Melero I
Cancer Discov; 2012 Jul; 2(7):608-23. PubMed ID: 22719018
[TBL] [Abstract][Full Text] [Related]
13. Ectopic expression of a T-box transcription factor, eomesodermin, renders CD4(+) Th cells cytotoxic by activating both perforin- and FasL-pathways.
Eshima K; Chiba S; Suzuki H; Kokubo K; Kobayashi H; Iizuka M; Iwabuchi K; Shinohara N
Immunol Lett; 2012 May; 144(1-2):7-15. PubMed ID: 22425747
[TBL] [Abstract][Full Text] [Related]
14. Nonreplicating recombinant vaccinia virus expressing CD40 ligand enhances APC capacity to stimulate specific CD4+ and CD8+ T cell responses.
Feder-Mengus C; Schultz-Thater E; Oertli D; Marti WR; Heberer M; Spagnoli GC; Zajac P
Hum Gene Ther; 2005 Mar; 16(3):348-60. PubMed ID: 15812230
[TBL] [Abstract][Full Text] [Related]
15. Focusing and sustaining the antitumor CTL effector killer response by agonist anti-CD137 mAb.
Weigelin B; Bolaños E; Teijeira A; Martinez-Forero I; Labiano S; Azpilikueta A; Morales-Kastresana A; Quetglas JI; Wagena E; Sánchez-Paulete AR; Chen L; Friedl P; Melero I
Proc Natl Acad Sci U S A; 2015 Jun; 112(24):7551-6. PubMed ID: 26034288
[TBL] [Abstract][Full Text] [Related]
16. NK and CD8+ T cell-mediated eradication of poorly immunogenic B16-F10 melanoma by the combined action of IL-12 gene therapy and 4-1BB costimulation.
Xu D; Gu P; Pan PY; Li Q; Sato AI; Chen SH
Int J Cancer; 2004 Apr; 109(4):499-506. PubMed ID: 14991570
[TBL] [Abstract][Full Text] [Related]
17. Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection.
Martínez Gómez JM; Koh VH; Yan B; Lin W; Ang ML; Rahim SZ; Pethe K; Schwarz H; Alonso S
Immunobiology; 2014 Jan; 219(1):78-86. PubMed ID: 24091276
[TBL] [Abstract][Full Text] [Related]
18. Chronic retroviral infection of mice promotes tumor development, but CD137 agonist therapy restores effective tumor immune surveillance.
Malyshkina A; Littwitz-Salomon E; Sutter K; Ross JA; Paschen A; Windmann S; Schimmer S; Dittmer U
Cancer Immunol Immunother; 2019 Mar; 68(3):479-488. PubMed ID: 30635687
[TBL] [Abstract][Full Text] [Related]
19. The CD137 Ligand Is Important for Type 1 Diabetes Development but Dispensable for the Homeostasis of Disease-Suppressive CD137
Foda BM; Ciecko AE; Serreze DV; Ridgway WM; Geurts AM; Chen YG
J Immunol; 2020 Jun; 204(11):2887-2899. PubMed ID: 32295876
[TBL] [Abstract][Full Text] [Related]
20. Deciphering CD137 (4-1BB) signaling in T-cell costimulation for translation into successful cancer immunotherapy.
Sanchez-Paulete AR; Labiano S; Rodriguez-Ruiz ME; Azpilikueta A; Etxeberria I; Bolaños E; Lang V; Rodriguez M; Aznar MA; Jure-Kunkel M; Melero I
Eur J Immunol; 2016 Mar; 46(3):513-22. PubMed ID: 26773716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
